Meta-analysis of 13 trials finds SGLT2 inhibitors reduce heart failure hospitalization in myocardial infarction.

This publication is a meta-analysis evaluating the effects of sodium–glucose cotransporter 2 inhibitors in patients with myocardial infarction. The scope encompasses 13 randomized controlled trials with a total sample size of 22,238 patients. The intervention involved SGLT2 inhibitors combined with conventional therapy compared against conventional therapy alone. The review synthesizes evidence regarding cardiovascular and safety endpoints. Evidence was pooled to determine overall treatment effects.

The primary outcome analysis indicates a significant reduction in the incidence of hospitalization for heart failure. The reported effect size is a relative risk of 0.76 with a 95% confidence interval of 0.68–0.84. Secondary outcomes assessed included all-cause mortality, major adverse cardiovascular events, left ventricular ejection fraction, N-terminal pro-B type natriuretic peptide, and low-density lipoprotein cholesterol. These metrics provide a comprehensive view of clinical impact and safety.

Several points regarding data availability are noted in the source text. Follow-up duration was not reported, and the p-value for the primary outcome was incomplete. Safety results, including renal dysfunction, hepatic dysfunction, urinary tract infection, and glycemia-related adverse events, were assessed but results were not reported in the abstract. Limitations were not reported in the provided text.

Clinicians should interpret these findings within the context of the reported limitations. While the meta-analysis is based on randomized controlled trials, the absence of complete safety and follow-up data requires caution. Further information is needed to fully assess tolerability and long-term outcomes. Clinical decisions should weigh these incomplete data carefully against potential benefits and risks.